Notably, in the current study, we revealed that CD36 peptide treatment effectively mitigated obesity-associated non-alcoholic fatty liver disease (NAFLD), as evidenced by reduced plasma ALT and AST levels, as well as decreased liver fat accumulation. The gene discussed is CD36; the disease is obesity due to melanocortin 4 receptor deficiency.